Compare ARK Genomic Revolution ETF (ARKG) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Beyond Meat Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Beyond Meat Inc trades at $0.66 (market cap $338.06M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BYND | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $4.28 |
52-Week Low | $23.09 | $0.52 |
Market Cap | — | $338.06M |
Enterprise Value | — | $648.06M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BYND trades at $0.656, down 2.77% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a net income margin of 79.49% but negative operating cash flow of -$144.93M in 2025. Recent product expansions include Beyond Steak Filet at Meijer and Wegmans, while earnings have been volatile with two misses and one beat in the last four quarters.
The outlook remains challenging with 57% analyst sell ratings and declining revenue trends. Key risks include persistent cash burn and competitive pressures. Upside potential hinges on successful turnaround efforts through new product launches and cost management, but the stock faces significant headwinds near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
